| P | OR | 95 % CI |
---|---|---|---|
Total | |||
Age | 0.385 | Â | Â |
 ≤40 years |  | 1 |  |
 >40 years | 0.385 | 0.767 | 0.423-1.394 |
Menopausal status | 0.518 | Â | Â |
 Pre-menopausal |  | 1 |  |
 Post-menopausal | 0.518 | 0.843 | 0.502-1.416 |
Tumor Size | 0.029 | Â | Â |
 T1 |  | 1 |  |
 T2 | 0.052 | 0.500 | 0.248-1.007 |
 T3 | 0.014 | 0.369 | 0.167-0.815 |
 T4 | 0.008 | 0.282 | 0.111-0.716 |
Nodal status | 0.432 | Â | Â |
 N0 |  | 1 |  |
 N1 | 0.493 | 0.802 | 0.426-1.508 |
 N2 | 0.701 | 1.308 | 0.332-5.147 |
 N3 | 0.328 | 1.171 | 0.564-5.561 |
Hormone receptor status | <0.001 | Â | Â |
 Negative |  | 1 |  |
 Positive | <0.001 | 0.307 | 0.182-0.518 |
Regimens | <0.001 | Â | Â |
 Cyclophosphamide, epirubicin and 5-fluorouracil |  | 1 |  |
 Cyclophosphamide, epirubicin and 5-fluorouracil followed by paclitaxel or docetaxel and epirubicin | 0.158 | 4.779 | 0.544-42.018 |
 Navelbine and epirubicin | 0.094 | 6.047 | 0.738-49.558 |
 Paclitaxel and carboplatin or paclitaxel and cisplatin | 0.006 | 16.479 | 2.236-121.451 |
Cycles | 0.029 | Â | Â |
 3-4 |  | 1 |  |
 1-2 | 0.018 | 0.176 | 0.042-0.740 |
 5-6 | 0.143 | 0.577 | 0.264-1.261 |